The racemic mixture, [6RS]-5-formyltetrahydrofolate, is widely used clinically. In human subjects, orally-administered pure unnatural C-6 isomers, [6R]-5-formyltetrahydrofolate and [6S]-5,10-methenyltetrahydrofolate, were recently shown to be metabolized to the natural isomer, [6S]-5-methyltetrahydrofolate. We re-analysed the data from human studies published during the past four decades in which oral doses (#10 mg) of racemic mixtures of these folates were used. We re-evaluated the data to determine whether these racemic mixtures are only 50 % bioactive or, as we now predict, more than 50 % bioactive. Our analyses indicate that, in human subjects, oral doses of the racemic mixture of the two formyltetrahydrofolates are 20±84 % more bioactive than would be predicted. These data are consistent with the following pathway: chemical conversion of these folates to 10-formyltetrahydrofolate; oxidation of 10-formyltetrahydrofolate to 10-formyldihydrofolate; subsequent enzymic conversion of 10-formyldihydrofolate to dihydrofolate by 5-amino-4-imidazolecarboxamide ribotide transformylase; and finally the well-established metabolism of dihydrofolate to [6S]-5-methyltetrahydrofolate. An additional review of the literature supports the in vivo oxidation of 10-formyltetrahydrofolate occurring to a certain extent, as 10-formyl-folic acid is rapidly formed after the administration of folic acid (pteroylglutamic acid) or 5-formyltetrahydrofolate in human subjects. The dogma that an oral dose of the unnatural C-6 isomer of 5-formyltetrahydrofolate is not bioactive in human subjects does not withstand scrutiny, most probably due to the previously unrecognized in vivo oxidation of 10-formyltetrahydrofolate. This discovery unveils new folate metabolism in human subjects.
Bioactive [6S]-5-formyltetrahydrofolate (5-HCO-H 4 folate) in bacteria was first isolated by Sauberlich & Baumann (1948) . The chemically synthesized racemic mixture, [6RS]-5-HCO-H 4 folate, has been widely used in combination with methotrexate and 5-fluorouracil in cancer chemotherapy. It was considered to have only 50 % of the bioactivity when compared with the natural isomer (Keresztesy & Silverman, 1951) . Baggott &Tamura (1999) , however, recently demonstrated that the pure unnatural isomers, [6R]-5-HCO-H 4 folate and [6S]-5,10-methenyltetrahydrofolate (5,10-CH=H 4 folates), are metabolized and become bioactive in human subjects, because an increase in microbiologically-active folates in plasma occurs after oral administration.
[6S]-5-Methyltetrahydrofolate (5-CH 3 -H 4 folate) accounted for the majority of this increase. They proposed an explanation which included the following steps. First, the well-known chemical formation of 10-formyltetrahydrofolate (10-HCO-H 4 folate) from 5-HCO-H 4 folate and 5,10-CH=H 4 folate takes place due to the changes in pH in the upper gastrointestinal tract (chemical reactions 1 and 2, Fig. 1 ). This process has been described by Beavon & Blair (1972) . Second, enzymic or chemical oxidation of 10-HCO-H 4 folate to 10-formyldihydrofolate (10-HCO-H 2 folate) subsequently occurs (reaction 3, Fig. 1 ). Third, the enzymic conversion of 10-HCO-H 2 folate to dihydrofolate is catalysed by 5-amino-4-imidazolecarboxamide ribotide transformylase (Baggott et al. 1995; Baggott & Johanning, 1999) , and dihydrofolate reductase reduces dihydrofolate to tetrahydrofolate (reactions 4 and 5 respectively, Fig. 1 ). Finally, tetrahydrofolate is converted to [6S]-5-CH 3 -H 4 folate by the well-known enzymic reactions involving serine hydroxymethyltransferase and 5,10-methylenetetrahydrofolate (5,10-CH 2 -H 4 folate) reductase (reactions 9 and 8 respectively, Fig. 1 ). Thus, these investigators concluded that the combination of these chemical and enzymic reactions would account for the increase in plasma [6S]-5-CH 3 -H 4 folate in subjects given oral doses of the pure unnatural isomers of 5-HCO-H 4 folate and 5,10-CH=H 4 folate (Baggott & Tamura, 1999) . In contrast, the naturally occurring isomer, [6S]-5-HCO-H 4 folate, can be metabolized to [6S]-5-CH 3 -H 4 folate through a relatively short enzymic pathway involving 5,10-CH=H 4 folate synthetase, 5,10-CH 2 -H 4 folate dehydrogenase and 5,10-CH 2 -H 4 folate reductase (reactions 6, 7 and 8 respectively, Fig. 1 ). Other possible pathways for the conversion of 5-HCO-H 4 folate to 5-CH 3 -H 4 folate include the reaction catalysed by 5,10-CH=H 4 folate cyclohydrolase (reaction 10, Fig. 1 ). Baggott & Tamura (1999) (Baker et al. 1965 (Baker et al. , 1994 Perry & Chanarin, 1970; Pratt & Cooper, 1971; Brown et al. 1973; Ratanasthien et al. 1974) . These investigators determined the increment of microbiologically active serum/plasma folate concentrations following the oral dose. We have critically re-analysed published data of these human studies and re-evaluated whether these racemic mixtures are only 50 % metabolized and bioactive or, as we now predict, more than 50 % bioactive. We limit our analyses to the studies using oral folate doses of 10 mg (22´7 mmol) or less to minimize artifacts possibly caused by unphysiologically large doses. We calculated the area under the curve using replotted data in figures or tables of the publications cited here. The area consisting of rectangles and triangles was computed after subtracting baseline values. Baker et al. (1965) administered 5´0 mg (11´3 mmol) folic acid (pteroylglutamic acid) and 10 mg (22´7 mmol)
[6RS]-5-HCO-H 4 folate to subjects by the oral and intravenous routes using a paired-study design. The doses of these two folates differed, as it was assumed that only the naturally occurring C-6 isomer of 5-HCO-H 4 folate would be bioactive. Serum folate concentrations were measured by microbiological assay with Lactobacillus casei for 8 h after each dose. The calculated area under the curve for the orally administered [6RS]-5-HCO-H 4 folate is larger than that of folic acid (Table 1 ). In contrast, the area under the curve for the intravenous route is similar for both folates. Based on these analyses, we conclude that the orally administered racemic mixture of 5-HCO-H 4 folate has a bioactivity almost equal to that of the same amount of folic acid. In contrast, the bioactivity of the intravenous dose of [6RS]-5-HCO-H 4 folate is approximately half that of folic acid. It is now apparent that the oral route must have allowed the unnatural isomer of [6RS]-5-HCO-H 4 folate to be converted to bioactive folates as stated earlier. In addition, the results of differential microbiological assay using L. casei and Enterococcus hirae (formerly known as Streptococcus faecalis) indicated that the majority of the serum folate was [6S]-5-CH 3 -H 4 folate following the independent oral dose of both folates. This finding is consistent with the metabolic pathways proposed by Baggott & Tamura (1999) and their results.
Using small oral doses of folic acid (10 mg/kg body weight) and [6RS]-5-HCO-H 4 folate (20 mg/kg) Perry & Chanarin (1970) conducted a similar study by monitoring serum folate concentrations for 3 h after the dose. The doses differed again because they assumed that only half the racemic mixture was bioactive. As shown in Table 1 , the relative bioactivity of [6RS]-5-HCO-H 4 folate is 1´71, which is higher than the predicted value of 1´0. Differential microbiological assay indicated that the majority of the serum folate was [6S]-5-CH 3 -H 4 folate after the dose of either compound. Pratt & Cooper (1971) administered 1´0 mg (2´27 mmol) folic acid and 2´0 mg (4´54 mmol) [6RS]-5-HCO-H 4 folate to subjects, again maintaining a 1:2 ratio to correct for the presumed bioactivity of this racemic mixture. Plasma folate concentrations were measured for 3 h after the dose. Their data indicate a relative bioactivity of 1´42 for the racemic mixture (Table 1 ). The majority of the plasma folate was also found to be [6S]-5-CH 3 -H 4 folate in this study. Brown et al. (1973) measured the maximum increases in serum folate concentrations at two time points (1 and 2 h) following independent oral doses of only 0´3 mg (0´68 mmol) folic acid, [6RS]-5-HCO-H 4 folate and [6RS]-5,10-CH=H 4 folate using a paired-study design. As sequential serum folate values were not reported, only mean maximum increases in total serum folates are presented in Table 1 . The oral dose of [6RS]-5-HCO-H 4 folate produced a slightly greater response than folic acid itself, and an even greater response was observed with [6RS]-5,10-CH=H 4 folate. These authors noted in the discussion that 5,10-CH=H 4 folate was better absorbed when compared with folic acid. This observation is also consistent with a pathway for the conversion of the unnatural isomer, [6S]-5,10-CH=H 4 folate, to bioactive folates as discussed earlier. Ratanasthien et al. (1974) reported the increase in serum folate concentrations after independent oral doses of 10 mg folate is set at 1´00 and expected bioactivity of the racemic mixture assumes that only the naturally-occurring C-6 isomer is bioactive. Doses administered in mg or mg are slightly lower on a molar basis for the C 1 -substituted tetrahydrofolate when compared with folic acid. § Only mean maximum increases in serum folate concentrations are available from this study. Finally, Baker et al. (1994) measured the increase in plasma total folate and [6S]-5-CH 3 -H 4 folate of portal blood following the oral administration of 10 mg [6RS]-5-HCO-H 4 folate in one group of subjects and 5´0 mg folic acid in another group. At 30 min after the dose the increases in both total folate and [6S]-5-CH 3 -H 4 folate were two to three times higher in subjects given the [6RS]-5-HCO-H 4 folate dose when compared with those given the folic acid dose. At the 60 min point the increases were similar in both groups. Their data also suggest that the unnatural isomer, [6R]-5-HCO-H 4 folate, was converted to bioactive [6S]-5-CH 3 -H 4 folate, although the data allow comparisons only between the 30 and 60 min time points after each dose (data not presented in Table 1 ).
We evaluated studies where the changes in serum or plasma folate concentrations were compared after various doses of folic acid or either pure unnatural isomers or racemic mixtures of formyltetrahydrofolate. The results of all studies uniformly indicate that a significant portion of the orally administered unnatural isomers of formyltetrahydrofolate is bioactive in human subjects. Among the studies reviewed here, the combination of independent oral and intravenous doses, the 8 h follow-up and a paired-study design by Baker et al. (1965) may be the strongest to support the hypothesis proposed by Baggott & Tamura (1999) . The similarity of the relative bioactivities of the intravenous dose of folic acid and [6RS]-5-HCO-H 4 folate virtually rules out the possibility that unnatural isomer, [6R]-5-HCO-H 4 folate, in high concentrations in the circulation, would enter tissues and displace pre-existing cellular folates back into the circulation. Furthermore, their pairedstudy design corrects for any genetic differences in physiology and folate metabolism.
In the proposed metabolic pathway for the unnatural C-6 optical isomers of formyltetrahydrofolate, the oxidation of 10-HCO-H 4 folate to 10-HCO-H 2 folate is a critical step (reaction 3, Fig. 1 ), as it removes the asymmetric centre at C-6, allowing further metabolism of the compound to [6S]-5-CH 3 -H 4 folate through well-established enzymic reactions. To our knowledge, the first evidence for the in vivo oxidation of 10-HCO-H 4 folate in human subjects was reported by McLean & Chanarin (1966) . They detected substantial amounts of radiolabelled 10-formyl-folic acid (10-HCO-folate) in a 4 h urine sample following an intravenous dose of radiolabelled folic acid (15 mg/kg). Their data suggest that the intravenously administered radiolabelled folic acid was first metabolized to 10-HCO-H 4 folate, and subsequently oxidized to 10-HCO-folate, with 10-HCO-H 2 folate as an obligate intermediate in this oxidation process. Pratt & Cooper (1971) used an oral dose of radiolabelled folic acid (1´0 mg) and detected radiolabelled 10-HCO-H 4 folate, 10-HCO-H 2 folate and 10-HCOfolate in 2 h bile samples. The detection of all three oxidation states of 10-formyl-substituted folates strongly suggests the existence of the in vivo oxidation process in human subjects. Whitehead et al. (1972) identified 10-HCO-folate in portal plasma collected 20 min after an oral dose of [6RS]-5-HCO-H 4 folate (2´0 mg). Their data suggest that the formation of 10-HCO-H 4 folate from 5-HCO-H 4 folate and the subsequent oxidation of 10-HCO-H 4 folate to 10-HCO-folate had occurred.
In a study of a patient with scurvy Stokes et al. (1975) suggested that the oxidation of 10-HCO-H 4 folate was sensitive to vitamin C nutriture. Before the patient was treated with ascorbic acid (150 mg/d) 10-HCO-folate was the major form of folate in a 24 h urine sample following an oral dose of [6RS]-5-HCO-H 4 folate (5´0 mg). However, the presence of [6S]-5-CH 3 -H 4 folate was not mentioned. On the other hand, [6S]-5-CH 3 -H 4 folate was the major form and no 10-HCO-folate was detected in a 24 h urine sample following oral [6RS]-5-HCO-H 4 folate (10 mg) after 6 d of ascorbic acid therapy. The authors did not mention the use of reducing agents, such as ascorbic acid, during the urinary collection. If we accept the data, one possible logical explanation for these findings is that the in vivo oxidation rate of 10-HCO-H 4 folate derived from the dose of 5-HCO-H 4 folate was much greater when the subject was vitamin C deficient. Again 10-HCO-H 2 folate is an obligate intermediate in the oxidation of 10-HCO-H 4 folate to 10-HCO-folate. One should not forget that the data demonstrating the presence of 10-HCO-folate in the studies noted earlier may be the result of oxidation during the analytical procedures. It remains to be tested, therefore, whether 10-HCO-folate detected in biological samples is exclusively formed by oxidation during the analyses.
In conclusion, a recent finding by Baggott & Tamura (1999) indicating that independent oral doses of pure unnatural C-6 isomers of formyltetrahydrofolate are bioactive in human subjects is consistent with results using racemic mixtures reported by other investigators. Additionally, there is evidence suggesting the occurrence of the in vivo oxidation of 10-HCO-H 4 folate in human subjects. This oxidation and the reaction catalysed by 5-amino-4-imidazolecarboxamide ribotide transformylase (reactions 3 and 4 in Fig. 1 ) are previously unrecognized folate metabolic steps in human subjects. The long-held belief that an oral dose of the unnatural isomer of 5-HCO-H 4 folate is inactive in human subjects appears to be wrong.
